オンコロジーIn Vivo（CRO）の世界市場規模：地域別、範囲および予測

オンコロジーIn Vivo（CRO）の世界市場規模および予測

オンコロジーIn Vivo（CRO）の世界市場規模は、2024年に20億7,000万米ドルと評価され、2024年から2031年にかけてCAGR 8.1％で成長し、2031年には36億1,000万米ドルに達すると予測されています。オンコロジー生体内研究や治療は、生体内で行われます。これは、マウスやヒトのような生きた動物を用いて、がんの挙動、進行、医薬品に対する反応を直接調査するもので、試験管内でのアプローチのみよりも正確に新しい治療法や介入策を設計・試験することを目的としています。

オンコロジーIn Vivoアプローチは、がんの進行と治療の成功を調査するために不可欠です。生きた動物モデルを用いて、腫瘍の開発、転移、治療効果を評価するのです。これらの技術は、標的療法の開発、薬物毒性の評価、がん生物学の知識の向上に役立ち、これらすべてが個別化医療の進展と患者の転帰の改善に貢献します。

オンコロジーin vivoアプローチは、より正確な腫瘍追跡、リアルタイムの薬物反応モニタリング、診断のための画像診断の改善を可能にすることで、個別化がん治療に革命をもたらすと思われます。これらの技術は、標的治療の改善、副作用の軽減、早期発見の簡素化をもたらし、より効果的で個別化されたがん治療を実現します。

オンコロジーIn Vivo（CRO）の世界市場力学

世界のがんベースの生体内（CRO）市場を形成している主な市場力学は以下の通りである：

主な市場促進要因

がん有病率の増加：

がんの有病率の増加：がんの有病率は国際的に上昇しています。この急増により、効果的な治療法や診断技術に対する需要が高まっています。In vivoモデルは創薬と市場開拓に不可欠であり、市場成長の原動力となっています。

バイオテクノロジーの進歩：

バイオテクノロジーの革新により、ますます複雑化し、オーダーメイドの医薬品開発が可能になっています。In vivoモデルは、こうした革新的な治療を評価するために不可欠であり、市場の成長を促進します。

研究開発投資の増加：

製薬企業やバイオテクノロジー企業は、がん研究に多額の投資を行っています。このような研究開発費の増加は、創薬や開発パイプラインに役立つ生体内モデルの需要を生み出しています。

薬事承認と市場参入：

がん治療薬の臨床試験が成功し、その後薬事承認が下りれば、市場参入となります。これらの治療薬の商業化には、in vivoモデルを用いて取得された実質的な前臨床データが必要とされることが多く、それによって市場の需要が高まる。

主な課題

高いコスト：

in-vivo腫瘍学研究の開発および実施には、モデル生物コスト、特殊な機器、スタッフのスキルなどの要因により、非常に高額な費用がかかります。そのため、小規模のバイオテクノロジー企業や学術機関にとっては障害となる可能性があります。

モデルの限界：

in vivoモデルは有用ではあるが、ヒトの腫瘍微小環境や病態進行を完全に再現することはできないです。このことは、研究結果のトランスレーショナルな意義や医薬品開発の成功率に影響を与える可能性があります。

倫理的配慮：

研究における動物の使用は倫理的問題を引き起こします。世間の注目、規制上の障害、強固な倫理的審査プロセスの必要性など、すべてがin vivo研究の時間とコストを増加させる可能性があります。

データの標準化と共有：

研究デザイン、データ報告、解析に一貫性がないため、結果の比較や再現が困難となります。確立されたプロトコルを開発し、データ共有を促進することは、医薬品開発を加速させる上で極めて重要です。

主要動向：

免疫腫瘍学への注目の高まり：

がんに対する免疫応答を調べるためのin vivoモデルの需要が高まっています。この動向は、免疫療法の成功例が増えていることや、革新的な免疫ベースの医薬品の前臨床試験の必要性が後押ししています。

個別化医療：

個別化医療が患者由来モデルの需要を牽引しており、ヒトの腫瘍生物学を効果的に表現するin vivoモデルの作製が重視されるようになっています。患者由来異種移植（PDX）モデルは、オーダーメイドの治療選択肢や薬剤開発を可能にするため、人気を集めています。

先端技術の採用：

AI、機械学習、画像処理などの最新技術の導入は、生体内研究に革命をもたらしています。これらの技術はデータ処理を増やし、創薬のスピードを上げ、臨床結果を予測するのに役立ちます。

規制コンプライアンスとデータインテグリティの重視の高まり：

規制当局は前臨床データをより詳細に分析しています。CROと製薬会社は、コンプライアンスと研究結果の信頼を確保するため、堅牢な品質管理システムとデータインテグリティの実践に投資しています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 オンコロジーIn Vivo（CRO）市場：サービスタイプ別

• 薬物動態試験
• 毒性試験
• 有効性試験
• バイオアナリシスおよび分析サービス

第5章 オンコロジーIn Vivo（CRO）市場：適応症別

• 固形がん
• 血液悪性腫瘍
• その他

第6章 オンコロジーIn Vivo（CRO）市場：エンドユーザー別

• 製薬会社およびバイオテクノロジー企業
• 開発業務受託機関（CRO）
• 学術・研究機関
• その他

第7章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• Charles River Laboratories International Inc.
• Envigo CRS
• Eurofins Scientific SE
• Icon plc
• Labcorp Co. Holdings
• Medpace Holdings Inc.
• PAREXEL International Corporation
• Pharmaceutical Product Development LLC（PPD）
• Syneos Health Inc.
• WuXi AppTec Co., Ltd.

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

Global Oncology Based In Vivo (CRO) Market Size and Forecast

Global Oncology Based In Vivo (CRO) Market size was valued at USD 2.07 Billion in 2024 and is projected to reach USD 3.61 Billion by 2031 growing at a CAGR of 8.1% from 2024 to 2031. Oncology-based in vivo research or treatment occurs within a living creature. It entails researching cancer's behavior, progression and response to medicines directly in living animals, such as mice or humans, in order to design and test new treatments and interventions more accurately than in vitro approaches alone.

Oncology-based in vivo approaches are critical for investigating cancer progression and therapy success. They use live animal models to assess tumor development, metastasis and therapy response. These technologies aid in the development of targeted therapies, the assessment of drug toxicity and the knowledge of cancer biology, all of which contribute to the advancement of personalized medicine and better patient outcomes.

Oncology-based in vivo approaches will revolutionize individualized cancer treatment by allowing for more precise tumor tracking, real-time medication response monitoring and improved imaging for diagnosis. These technologies will improve targeted therapy, reduce side effects and simplify early detection, resulting in more effective and personalized cancer treatment.

Global Oncology Based In Vivo (CRO) Market Dynamics

The key market dynamics that are shaping the global oncology based in vivo (CRO) market include:

Key Market Drivers:

Increasing Cancer Prevalence:

Cancer prevalence is rising internationally. This surge increases the demand for effective therapies and diagnostic technologies. In vivo models are critical for drug discovery and development, which drives market growth.

Advances in Biotechnology:

Biotechnology innovations are enabling the development of increasingly complicated and tailored medicines. In vivo models are critical for assessing these innovative treatments and driving market growth.

Increasing R&D Investment:

Pharmaceutical and biotechnology corporations are investing considerably in cancer research. This increasing R&D spending creates a demand for in vivo models to help drug discovery and development pipelines.

Regulatory Approval and Market Entry:

Successful clinical studies and subsequent regulatory approvals for oncology treatments result in market launch. Commercialization of these medications frequently requires substantial preclinical data acquired utilizing in vivo models, thereby enhancing market demand.

Key Challenges:

High Costs:

Developing and carrying out in vivo oncology studies is exceedingly expensive because to factors such as model organism costs, specialized equipment and staff skills. This may impede smaller biotech enterprises and academic organizations.

Model Limitations:

While in vivo models are useful, they cannot fully replicate human tumor microenvironments and disease progression. This can have an impact on the translational significance of study findings and drug development success rates.

Ethical Considerations:

Using animals in research creates ethical issues. Public attention, regulatory impediments and the requirement for robust ethical review processes can all add to the time and cost of in vivo research.

Data Standardization and Sharing:

Inconsistent study design, data reporting and analysis make it difficult to compare and reproduce results. Creating established protocols and encouraging data sharing crucial for accelerating drug development.

Key Trends:

Increasing Focus on Immuno-oncology:

The demand for in vivo models to investigate immune responses to cancer is increasing. This trend is being pushed by the increasing success of immunotherapy and the necessity for preclinical testing of innovative immune-based medicines.

Personalized Medicine:

Personalized medicine is driving the demand for patient-derived models there is a rising emphasis on creating in vivo models that effectively represent human tumor biology. Patient-derived xenograft (PDX) models are gaining popularity since they enable tailored treatment options and drug development.

Adoption of Advanced Technology:

The incorporation of modern technology such as AI, machine learning and imaging is revolutionizing in vivo research. These techniques increase data processing, speed up drug discovery and help anticipate clinical outcomes.

Increasing Emphasis on Regulatory Compliance and Data Integrity:

Regulatory authorities are analyzing preclinical data more closely. CROs and pharmaceutical companies are investing in robust quality management systems and data integrity practices to ensure compliance and trust in research findings.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Oncology Based In Vivo (CRO) Market Regional Analysis

Here is a more detailed regional analysis of the global oncology based in vivo (CRO) market:

North America:

According to Verified Market Research, North America is expected to dominate the global oncology based in vivo (CRO) market.

North America is predicted to dominate the global oncology-based in vivo Contract Research Organization (CRO) market, owing to its strong healthcare infrastructure, large investment in cancer research and concentration of top pharmaceutical and biotechnology businesses.

The region's advanced technology, skilled labor and regulatory support contribute to its market supremacy. Furthermore, North America's large clinical trial networks and early adoption of novel oncology treatments add to its dominance.

As the region continues to push advances in customized medicine and targeted therapeutics, it stays at the forefront of the oncology-based in vivo CRO market, influencing worldwide trends and standards.

Asia Pacific:

According to Verified Market Research, Asia Pacific is fastest growing region in global oncology based in vivo (CRO) market.

The Asia-Pacific region is the fastest-growing market for oncology-based in vivo contract research organizations (CROs), driven by rising cancer rates and expanding healthcare infrastructure.

Rapid economic growth, increasing investment in medical research and advances in imaging and diagnostic technology are driving this expansion. Furthermore, improved regulatory conditions and an increasing emphasis on personalized treatment contribute to the region's expansion.

As more pharmaceutical and biotech businesses seek cost-effective and novel research solutions, Asia-Pacific is emerging as a key hub for oncology-based in vivo investigations, providing considerable growth and development prospects in the CRO sector.

Global Oncology Based In Vivo (CRO) Market: Segmentation Analysis

The Global Oncology Based In Vivo (CRO) Market is segmented based on Indication, Model and Geography.

Global Oncology Based In Vivo (CRO) Market, By Indication

• Blood Cancer
• Solid Tumors

Based on Indication, the Global Oncology Based In Vivo (CRO) Market is separated into Blood Cancer and Solid Tumors. Solid tumors dominate the worldwide oncology-based in vivo CRO market due to their higher occurrence and the considerable research needed for targeted medications and individualized treatments. While blood cancers are substantial, they represent a lower fraction of market activity when contrasted to the broader and more diverse research focus on solid tumors.

Global Oncology Based In Vivo (CRO) Market, By Model

• Syngeneic Model
• Xenograft

Based on Model, Global Oncology Based In Vivo (CRO) Market is divided into Syngeneic Model and Xenograft. The xenograft model presently dominates the worldwide oncology-based in vivo CRO market due to its superior capacity to imitate human tumor microenvironments. This paradigm is preferred for assessing therapeutic efficacy and mechanisms in cancer research, as it provides useful information for designing targeted therapies and individualized treatments.

Global Oncology Based In Vivo (CRO) Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on the Geography, the Global Oncology Based In Vivo (CRO) Market divided into North America, Europe, Asia Pacific and Rest of the World. North America leads the worldwide oncology-based in vivo CRO market due to its advanced research infrastructure, significant expenditure in cancer research and established healthcare systems. This region leads in market share and innovation, although the Asia-Pacific area is rapidly expanding and gaining prominence.

Key Players

• The Global Oncology Based In Vivo (CRO) Market study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Charles River Laboratory, ICON Plc, Thermo Fisher Scientific, Inc., Eurofins Scientific, Taconic Biosciences, Crown Bioscience, LabCorp, WuXi AppTec, EVOTEC, The Jackson Laboratory.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

• Global Oncology Based In Vivo (CRO) Market Recent Developments
• In November 2023, Crown Bioscience introduced the OrganoidXploreTM service. Our organoid panel screening tool provides rapid, reliable and clinically relevant results, accelerating preclinical research. Oncology drug discovery is changing the landscape of cancer treatment development.
• In October 2023, Coeptis Therapeutics Holdings, Inc. disclosed research on the potential of the SNAP-CAR T-cell platform to target multiple antigens. The study used SNAP-CAR technology to show its adaptive antigen-targeting capabilities in human tumor xenograft models, both in vivo and in vitro.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Oncology Based In-Vivo CRO Market, By Service Type

• Pharmacokinetic Studies
• Toxicology Testing
• Efficacy Studies
• Bioanalysis and Analytical Services

5. Oncology Based In-Vivo CRO Market, By Indication

• Solid Tumors
• Hematological Malignancies
• Others

6. Oncology Based In-Vivo CRO Market, By End User

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic and Research Institutes
• Others

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Charles River Laboratories International Inc.
• Envigo CRS
• Eurofins Scientific SE
• Icon plc
• Labcorp Co. Holdings
• Medpace Holdings Inc.
• PAREXEL International Corporation
• Pharmaceutical Product Development LLC (PPD)
• Syneos Health Inc.
• WuXi AppTec Co., Ltd.

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References